CJC-1295 NO DAC (Mod GRF 1-29) (5mg)

CJC-1295 Peptide (No DAC) 

CJC-1295 (No DAC) is a synthetic peptide derivative of human growth hormone-releasing hormone (GHRH), composed of 29 amino acids. It is also referred to as Modified GRF (1-29) or tetrasubstituted GRF (1-29). Unlike CJC-1295 with DAC (Drug Affinity Complex), this peptide lacks the long-acting half-life extension provided by DAC, making it a shorter-acting GHRH analog suitable for research in growth hormone (GH) regulation and pulsatility.

Chemical Properties

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Weight: 3367.9 g/mol

• Other Names: Modified GRF (1-29), CJC-1295 Without DAC

• Peptide Type: Synthetic GHRH analog

Mechanism of Action

CJC-1295 (No DAC) is designed to mimic the first 29 amino acids of endogenous GHRH, which are sufficient to activate GHRH receptors on anterior pituitary somatotroph cells. Modifications in four amino acid positions are intended to increase peptide stability against enzymatic degradation:

1. 2nd Position: L-alanine → D-alanine → enhances resistance to degradation.

2. 8th Position: Asparagine → Glutamine → minimizes amide hydrolysis.

3. 15th Position: Glycine → Alanine → may enhance bioactivity.

4. 27th Position: Methionine → Leucine → prevents oxidation.

Upon binding to GHRH receptors, CJC-1295 (No DAC) may:

• Activate G-proteins, inducing secondary messenger production (e.g., cAMP, IP3).

• Stimulate protein kinases, leading to phosphorylation of transcription factors.

• Enhance GH gene transcription and secretion from somatotrophs.

• Promote downstream effects via the GH-IGF-1 axis, including tissue growth and metabolism.

Research and Functional Insights

1. Pituitary and GH Secretion

   • Increases mean GH release by ~70–107% over 12 hours in experimental models.

   • Raises IGF-1 levels by ~28%, reflecting enhanced GH axis activity.

   • Promotes skin fibroblast proliferation and muscle tissue hypertrophy, potentially increasing lean mass.

2. GH Pulsatility

   • Supports physiological pulsatile GH secretion, which may benefit anabolic and regenerative processes.

3. Cardiovascular and Intestinal Effects

   • Preliminary research in murine models suggests potential support for heart rate and cardiac function post-injury.

   • Possible interactions with VPAC(1)-R in smooth intestinal muscles, potentially affecting bowel motility.

4. Combination Potential

   • Synergistic effects observed when combined with growth hormone secretagogues (GHSs), such as Ipamorelin.

   • Dual activation of GHRH and ghrelin receptors may further amplify GH release.

Applications in Research

• GH-IGF-1 axis studies

• Muscle growth, lean mass, and skin tissue regeneration

• Pituitary receptor signaling research

• GH pulsatility and endocrine modulation

• Cardiac repair and tissue regenerative studies

• Peptide combination studies with GHSs

Important Notice

CJC-1295 (No DAC) is for research and laboratory use only.
It is not approved for human consumption or medical use. Proper laboratory handling and safety protocols should be followed.

References

1. National Center for Biotechnology Information. PubChem Compound Summary for CID 91976842, CJC-1295 Without DAC.

2. Clark, R. G., Robinson, I. C. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature. 1985;314:281–283.

3. The Discovery of Growth Hormone-Releasing Hormone: An Update. Wiley Online Library.

4. Martin, B., et al. Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular Medicine. 2005;7(1–2):3–36.

5. Newton, A. C., Bootman, M. D., Scott, J. D. Second Messengers. Cold Spring Harb Perspect Biol. 2016;8(8):a005926.

6. Khorram, O., Laughlin, G. A., Yen, S. S. Endocrine and metabolic effects of long-term administration of [Nle27]GRF-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472–1479.